Ranibizumab Injection
Original Article Intracameral ranibizumab injection combined with Ex-PRESS mini glaucoma shunt implantation versus Ahmed valve surgery in treatment of neovascular glaucoma
... ICR injection combined with Ex-PRESS mini glaucoma shunt implantation in treating NVG patients, and which we also compared with treatment of Ahmed valve ...ICR injection reduces new vessels of the iris, ICR ...
7
Electrophysiologic changes after intravitreal ranibizumab injection for the treatment of choroidal neovascular membrane (CNVM)
... injected intravitreally at 4.0 mm from the limbus in phakic eyes and at 3.5 mm in pseudophakic eyes. The patients were then instructed to take an antibiotic for 1 week and were scheduled for further postoperative visits ...
6
Intravitreal ranibizumab injection combined trabeculectomy versus Ahmed valve surgery in the treatment of neovascular glaucoma: assessment of efficacy and complications
... Thirty-six NVG patients (37 eyes) were included in the study. Eighteen NVG eyes underwent IVR injection and subsequent trabeculectomy (IVR group). Nineteen eyes underwent Ahmed valve implantation surgery (Ahmed ...
7
A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
... In 2012, a systematic review and meta-analysis con- ducted by the Health Intervention and Technology As- sessment Program (HITAP) [9] indicated that IVB was superior to non-pharmaceutical interventions in nAMD and DME. ...
14
Retinal Functional Changes Measured by Microperimetry after Intravitreal Ranibizumab Injection and Sulfotanshinone Sodium Injection for Macular Edema Secondary to Retinal Vein Occlusion
... Here, we observed that BCVA and CRT outcomes were significantly improved in all patients after treatment (t = 7.74, p < 0.01; t = 8.24, p < 0.01), demonstrating that IVR injection and SS injection ...
6
Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
... intravitreal injection was performed every ...to ranibizumab, the first ranibizumab injection was performed one month after the last bevacizumab injection in order to avoid a time ...
5
Early changes in macular optical coherence tomography parameters after Ranibizumab intravitreal injection in patients with exsudative age-related macular degeneration
... Methods: This was an interventional, non randomized, open label prospective study, where we evaluated 20 eyes of 20 patients affected by exudative age-related macular degeneration. These patients were treated with ...
5
A Long Term Study of Efficacy of Patients with Macular Edema Secondary to BRVO Treated with Ranibizumab Combined with Compound Salvia
... including ranibizumab and beva- cizumab, have been the most promising treatment of macular ...intravitreal ranibizumab injection combined with intravenous compound salvia injection drip can ...
6
The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
... first ranibizumab injection (Figure ...of ranibizumab administration in the VMA ( + ) group was ...intravitreal injection on the basis of OCT ...
5
Current perspectives on ranibizumab
... Antibody Ranibizumab in the Treatment of Neovascular AMD [MARINA], A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients with Subfoveal Neovascular Age- related Macular ...
10
Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion
... intravitreal injection. Intravitreal injection of 0.5 mg/0.05 mL ranibizumab was performed under sterile conditions with a 30-gauge ...the injection, ciprofloxacin ointment was given for 1 ...
6
Human Herpesvirus-6 corneal Endotheliitis after intravitreal injection of Ranibizumab
... of ranibizumab in the left eye for 2 years according to a Pro Re Nata treatment regimen for macular edema associated with branch retinal vein ...last injection, the patient presented with pain and decreased ...
7
Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia
... ranibizumab injection, reduction of hyperfluorescent dots in early phase angiograms was manifest in all eyes, revealing that the majority of the telangiectatic capillary network in the perifoveal area had ...
6
Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation
... Drug injection 1 week before laser photocoagulation effec- tively inhibited the growth of RNVs, reduced vascular leakage, and relieved retinal edema, thereby lowering the laser energy required, protecting the ...
7
1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy
... with ranibizumab was highly successful in treating single small polyp PCVs, but it appeared to be less effective if there were BVN and/or multiple polyps were ...
7
Original Article The clinical efficacy of vitreous injection of ranibizumab in patients with ocular fundus disease and its effect on hemorheology
... diseases. Ranibizumab can in- hibit the formation of new blood vessels by binding to VEGF, which promotes the rapid absorption of retinal fluids and reduces blood rheology such as red blood viscosity and plas- ma ...
8
Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study
... Participants and methods: One hundred and fifty eyes of 150 IVI-naïve patients with macular edema caused by various pathological conditions (age-related macular degeneration, central or branch retinal vein occlusion, and ...
9
Photodynamic therapy versus anti-vascular endothelial growth factor agents for polypoidal choroidal vasculopathy: A meta-analysis
... The optimum treatment for PCV remains controver- sial. To date, a number of studies have compared the anatomic and functional outcomes of PDT and intravit- real injection of anti-VEGF agents for treating PCV [7, ...
9
Aflibercept in wet AMD: specific role and optimal use
... ticals Inc, FL, USA and Pfizer Inc, New York, NY, USA) was the first VEGF inhibitor approved by the US Food and Drug Administration (FDA). Important advances in the on- label treatment of CNV in AMD have been achieved ...
12
Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
... By matching health claims with clinical data we were able to study cost consequences of treatment in a real life setting in a straightforward fashion. This dataset al- lows studying and contextualising the variability of ...
6